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Abstract: Endocrine disrupting chemicals (EDCs) are exogenous chemicals that may occur naturally
(e.g., phytoestrogens), while others are industrial substances and plasticizers commonly utilized
worldwide to which human exposure, particularly at low-doses, is omnipresent, persistent and occurs
in complex mixtures. EDCs can interfere with/or mimic estrogenic hormones and, consequently, can
simultaneously trigger diverse signaling pathways which result in diverse and divergent biological
responses. Additionally, EDCs can also bioaccumulate in lipid compartments of the organism
forming a mixed “body burden” of contaminants. Although the independent action of chemicals has
been considered the main principle in EDCs mixture toxicity, recent studies have demonstrated that
numerous effects cannot be predicted when analyzing single compounds independently. Co-exposure
to these agents, particularly in critical windows of exposure, may induce hazardous health effects
potentially associated with a complex “body burden” of different origins. Here, we performed an
exhaustive review of the available literature regarding EDCs mixtures exposure, toxicity mechanisms
and effects, particularly at the most vulnerable human life stages. Although the assessment of
potential risks to human health due to exposure to EDCs mixtures is a major topic for consumer
safety, information regarding effective mixtures effects is still scarce.
Keywords: endocrine disrupting chemicals (EDCs); mixtures; biomonitoring; windows of exposure;
risk assessment
1. Introduction
Endocrine disruption associate to environmental exposures has been acknowledged for several
years. During the last decades, endocrine disruption research has been directed to the reproductive
system, since an increase of reproductive system health problems was demonstrated. Additionally,
the increment of hormone-related cancers (e.g., testicular and breast cancers), decreased semen
quality, and incidence of birth anomalies in genital organs may also be correlated to environmental
factors [1]. Our concern with human exposure to Endocrine Disrupting Chemicals (EDCs) derives
from: (i) evidence regarding molecular mechanisms correlated to effects at very low doses; (ii) in vitro
effects in animal models resultant from doses within the range of human exposure; and (iii) extensive
and prevalent human exposure to EDCs at concentrations that have been documented to endorse
adverse effects in animals [2]. The inadvertent exposure of humans to numerous chemicals through
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divergent routes establishes a “mixture” context that is the focus of our review paper. Similar to the
most recent trends explained in Evans et al. [3], we do not discuss commercial products with defined
ingredients, characterized as “intentional” mixtures. A mixture does not directly imply a risk to human
or environmental health per se, however existing experimental data regarding mixture effects of low
and/or ineffective levels highlight the urge to implement valuable and effective assessments with the
ability to evaluate whether more accurate estimations of risk should be produced by considering the
existent chemicals [4–6]. It is currently acknowledged that humans are exposed to diverse chemicals
through several exposure routes, which can be measured in human biological samples, including blood
and breast milk. However, the potential risk to human health associated to the acquired “body burden” of
contaminants is still not assessed or managed by regulatory organizations, or even routinely monitored.
2. EDCs State of the Art
Endocrine disruptors or endocrine disrupting chemicals are omnipresent exogenous compounds
with the ability to behave as biological signals and as a result can interfere with/or mimic endogenous
estrogenic hormones, acting as agonists or antagonists [7]. The U.S. Environmental Protection Agency
(EPA) classifies environmental EDCs as “an exogenous agent that interferes with production, release,
transport, metabolism, binding, action, or elimination of natural hormones in the body responsible
for the maintenance of homeostasis and the regulation of developmental processes”. Furthermore,
the International Programme on Chemical Safety (IPCS) defined possible EDC from actual EDC,
as “an exogenous substance or mixture that possesses properties that might be expected to lead
to endocrine disruption in intact organisms, or in progeny, or (sub) populations” [8]. Exposure to
these compounds is accountable for different and divergent biological responses associated with
the simultaneous and differential activation of specific signaling pathways in diverse cell types [9].
Although around 800 commercial substances are supposed to affect the endocrine system, only
a minor portion of these have been tested for possible hazardous effects [10]. Human exposure,
particularly at extremely low-doses, is generalized, persistent and occurs in different mixtures with
potential associated effects that may not be predictable when evaluating single compounds per se [11].
Therefore, the assessment of potential risks to human health resultant of exposure to EDCs and
mixtures is a key and foremost important subject for consumer safety. EDCs may occur naturally (e.g.,
phytoestrogens), whereas others are commercial substances and plasticizers globally utilized in the
plastic industry. EDCs comprise persistent organic pollutants (POPs) (e.g., polychlorinated biphenyls
(PCBs)), polychlorinated dibenzo-p-dioxins/furans (PCDDs/PCDFs), organochlorine pesticides (OCPs)
and polybrominated flame-retardants [12,13]. Diet, particularly ingestion of contaminated food, is
estimated to be the main source of human exposure to EDCs for all age groups [14]. It is important
to note that dietary habits are influenced by diverse factors such as socioeconomic status, culture and
religion as well as individual choices. These factors have a major impact on human daily consumption
of nutrients, bioactive constituents, residues and contaminants. Additionally, some foods of vegetable
origin are a source of natural endocrine-active substances (e.g., phytoestrogens) that can interact with
endogenous estrogen signaling pathways [12]. Currently, the worldwide spread of vegetarianism has
led to the increased intake of vegetables such as soybeans with a high content of genistein, one of the
most studied isoflavones associated with several biological activities, including as a phytoestrogen,
an antioxidant, and as an inhibitor of a broad range of tyrosine kinases [15–17].
Considering human exposure patterns through oral intake EDCs, can be separated in four
major categories:
− EDCs with bioaccumulation ability (e.g., polychlorinated biphenyls -PCBs-, polybrominated
flame retardants, perfluorinated chemicals);
− Compounds utilized in food production (e.g., pesticides);
− Chemicals present in food due to contact materials, processing aids, etc. (e.g., BPA); and
− Endocrine-active substances naturally present in food (e.g., genistein).
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Another significant source of human exposure to EDCs, besides dietary route, is the indoor
environment. Indoor air contamination in buildings and houses may induce airborne exposure
noticeably above background levels. One group of the relevant compounds associated with indoor
exposures are PCBs [18]. Although PCBs were banned in several countries due to indication of
environmental accumulation and potential hazardous health effects, these compound are currently
present in the environment, indoors and humans and are classified as persistent organic pollutants [18].
Exposures to PCBs have been positively correlated with adverse liver, kidney, endocrine, and
neurodevelopmental effects, and thyroid disruption has also been reported [19]. However, PCBs
effects on humans associated with acute exposures or long-term effects on reproduction are still a
matter of debate in the scientific community. Currently, the project HESPERUS is the first study that
tends to evaluate potential hazardous health effects of continuous exposure to the lower-chlorinated,
semi-volatile PCBs in indoor environments [18]. Thus, considering that EDCs are also detected in
waste water, drinking water, air and dust particles from both house dust samples and urban ambient
outdoor environment [20–22], non-dietary human exposure sources such as air or contact must not be
underestimated [23,24].
Furthermore, it is important to note that hormones, as well as EDCs responses, do not follow the
classical monotonic dose responses typically used in toxicological risk assessments but non-monotonic
dose responses (NMDR) curves which can result from multiple mechanisms [2,25]. The “low-dose”
effect was defined based on the Environmental Protection Agency (USEPA) criterion for low-dose
effects of EDCs as those observed at concentrations below the levels used for classical toxicological
assessments [26]. Remarkably, extremely low levels are able to stimulate receptor up-regulation,
resulting in response enhancement, whereas higher doses (within the classic toxicological range)
can induce receptor down-regulation, resulting in a diminished responses [27]. In single response
experiments, NMDR curves are a common finding for EDCs. An additional difficulty, however, is
correlated to the assessment of multiple outcomes as qualitatively divergent outcomes are frequently
observed at low and high EDCs exposures. One hypothesis for this phenomenon is that the patterns
of genes whose expression is affected by low doses of endogenous hormones may be divergent
from the set of genes altered by high concentrations. In increasing concentrations, hormones and
hormone-mimicking chemicals may signal different receptors, defined as receptor cross-talk [27].
In the case of the xenoestrogen BPA, NMDR have been demonstrated to emerge on exposed pituitary,
prostate and pancreatic cultured cells, since very low doses can induce significant effects that are
not detectable at higher concentrations (reviewed in [25]). Furthermore, EDCs effects can also be
mediated by mechanisms external to direct mediation by classical hormone receptors. Nonspecific
(non-receptor-mediated) effects may occur exclusively at high doses. Moreover, EDCs can also interact
with the synthesis or function of enzymes responsible for the synthesis or degradation of hormones
as well as of coregulatory proteins which interact with receptors and, in the situation of neurologic
actions, alter neurotransmitters and associated receptors [27]. Moreover, it is imperative to consider
that individuals environmentally exposed to EDCs may also be occupationally exposed, to the same
and/or different compounds which leads to the notion that the evaluation of potential aggregate
exposures is crucial for the development of an effective risk assessments.
3. Materials and Methods
An exhaustive search was performed for papers available in scientific databases reporting EDCs
mixtures effects and associated mechanisms. The articles presented and discussed were obtained using
diverse scientific databases such as PubMed and Google Scholar and using the keywords: Endocrine
disrupting chemicals (EDCs); EDCs Mixtures; Mixture Effects; Toxicity Mechanisms; Biomonitoring;
Risk Assessment and Critical Windows of Exposure. In our review, we considered experimental
studies, epidemiological studies and previous reviews published in 2000–2016. Inclusion and exclusion
criteria were established before bibliographic search. Studies published in languages other than
English were considered only if an abstract was available. The articles that, besides written in English,
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also reported findings regarding EDCs mixtures exposure, toxicity mechanisms and effects in vivo
and in vitro, biomonitoring in pregnant women, early life effects and reports of male vulnerability,
were chosen for further analysis. Regarding in vitro EDCs mixture effects in human cell lines, only
14 studies were considered, which are summarized in Table 1.
4. EDCs Mixtures Toxicity Mechanisms
Chemical regulation operates almost entirely on a chemical-by-chemical basis, however the
concern of whether this approach is suitably protective if different chemicals have the same toxic
effect remains. Humans are unquestionably exposed to numerous chemicals at a time, found in
food, air, drinking water, household, consumer products, and cosmetics [3]. Mixture risk assessment
(MRA) defines the assessment of the cumulative risk to human health or the environment due to
exposure to different chemicals via multiple routes [3]. The toxicological effects of compounds mixtures
can result in either independence (response additivity) or dose addition. Concentration (or dose)
addition has been used in association to mixtures of similar acting chemicals such as those interacting
with ER, while independent action has been employed for different acting compounds, including
compounds in a mixture that interact with dissimilar receptors or other molecular targets [28]. In 2011,
the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) accomplished an
extensive assessment of compounds mixture studies tested at concentrations in the range of the No
Observed Adverse Effect Level (NOAEL) or No Observed Effect Concentration (NOEC) or below
for each constituent in the mixture. As a result, the independent action of chemicals was considered
the main principle of mixture toxicity and the report stated that “there is no evidence that exposure
to complex mixtures of components, each well-regulated according to established risk assessment
approaches, would pose a health risk to humans” [29]. As similarly acting chemicals can substitute
one another, without decreased efficiency, combination effects can be predictable, even at doses
below NOAELs. Thus, classical risk assessment approaches focused on single chemicals assessments
are problematic, since considerations of individual NOAEL do not integrate potential risks without
information regarding simultaneous exposure to other occurring agents [6,30]. Additionally, the
World Health Organization (WHO) report on endocrine disrupting chemicals also specified: “ . . .
there is emerging evidence that many chemicals may act additively and, each at levels without
individual effect, could act together to cause health problems” [10]. EFSA considered that compounds
with equal effects in the same target organ are presumed to act in an additive way, even when
their chemical structures and molecular mechanisms are unlike (reviewed in [13]). The situation is
thought to be entirely different when exposure occurs with substances that have different modes
of action. Because these chemicals interact individually with different subsystems of the affected
organisms, the supposition is that, as long as the concentration of each constituent stays below
its NOAEL, mixtures pose no valuable health concerns [6]. However, some EDCs (e.g., BPA) can
bind to numerous hormone receptors. Similarly, the concept of threshold as it applies to EDCs is
complex and must be evaluated with caution [31]. Studies focused in evaluation of mixtures of
components with estrogenic, antiandrogenic, and thyroid-disrupting activities demonstrated the
utility of the concept of dose addition in expecting mixture effects, demonstrating that joint effects
occur even at levels below doses that induce observable effects (reviewed in [4]). Dose additivity
has been rationalized, particularly in the case of compounds competing independently for the same
receptor [32,33]. In human breast carcinoma MVLN cells and Chinese hamster ovary CHO-K1 cells,
mixtures of currently used pesticides, namely, bitertanol, propiconazole, cypermethrin, terbuthylazine,
bitertanol, propiconazole, cypermethrin, and malathion, demonstrated endocrine-disrupting potential
in vitro, potentially mediated via ER, AR and aromatase activities [34]. In multipotent murine
mesenchymal stem cells (C3H10T1/2), simultaneous exposure of BPA, diethylhexylphthalate (DEHP)
and tributyltin (TBT), known to interfere with adipogenesis, increased the development of adipocytes
and the expression of adipogenic marker genes [35]. Co-exposure to BPA and nonylphenol (NP)
endorsed an additive effect on some antioxidant parameters in zebrafish embryos [36]. In addition,
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a recent yeast estrogen assay (YES) that evaluated the estrogenic potential of mixtures of genistein,
BPA and/or trenbolone, which exert their estrogenic effects through analogous mechanisms (i.e.,
binding to estrogen receptor) demonstrated that the dose additivity of estrogenic mixtures of genistein,
BPA and/or trenbolone is established by receptor occupancy [37]. Additionally, a recent study
has also demonstrated that combined exposures to BPA and soy-based phytoestrogens results in
additive estrogenic effects which can play key roles in the etiology of estrogen-linked diseases, such
as breast cancer [38]. Conversely, other studies have demonstrated that dose additivity of estrogenic
mixtures is not the only mechanism of mixture toxicity, which leads to a controversy regarding the
effective effects of these mixtures for human health. In ovarian cancer cell line BG-1, genistein, was
reported to efficiently suppress BPA-induced ERα mediated proliferation through inhibition of cell
cycle progression [39]. Additionally, besides the fact that BPA can promote estrogen-like effects similar
to, or stronger than, E2 [40], it is also capable to interact with this endogenous hormone. In MCF-7
breast cancer cell line, combined exposure to BPA at low dose and E2 at physiological concentration
induces cell proliferation and decreases apoptosis [41]. In addition, in colon cancer cell line DLD-1 E2
pro-apoptotic action is antagonized by BPA through inhibition of cascade 3 activation [42]. A recent
study performed using a goldfish model demonstrated that mixture exposure effects are characterized
by a stress response that cannot be predicted from exposure to individual compounds, even in the
absence of further phenotypic features [43]. In addition, synergistic effects were observed for reactive
oxidative species (ROS) induction in human hepatocarcinoma (HepG2) cells exposed to perfluorinated
and brominated mixture in contrast to the effects of the individual mixtures [44]. Additionally, in male
Japanese medaka, the assessment of EDCs mixtures in hypothalamic–pituitary–gonadal axis gene
transcription also demonstrated that, although exposure to flutamide and vinclozolin per se resulted
in similar transcriptional responses, mixture effects could not be extrapolated based on the results
from single compounds [45].
Moreover, considering that many EDCs bioaccumulate in lipid compartments of organisms
forming a mixed “body burden” of contaminants of diverse origins, it is assured that the daily dose of
each compound alone is not the only one that should be taken into consideration [13]. Thus, mixture
effects of EDCs certainly extend considerably beyond the groups of chemicals with similar chemical
structures and molecular mechanisms, as summarized in Table 1 by in vitro studies that assessed EDCs
mixtures effects in human cell lines.
The debate on whether risks associated with low-level exposure to different chemicals can be
assessed without considering the mode of action of the chemicals present in the “cocktail of pollutants”
is still intense. In view of the variety of “real world” mixtures composed by several chemicals
with a multitude of dissimilar modes of action, divergent action of mixture constituents should be
considered as the default scenario [4]. Considering the limitations of the quantity of chemicals and
animals that can be manageable in laboratory experiments and the complexity of the assessment of
effective human in vivo concentrations, mixture effects at “realistic” levels are extremely difficult to
evaluate. However this may not present a definitive obstacle to risk assessment. The understanding of
the determinants of additive effects is now satisfactorily advanced to allow anticipation of mixture
effects through mathematical modeling. Difficulties present themselves, however, when appropriate
effect data for single EDCs are unavailable. In these cases, mixture effects cannot be predicted [6].
5. Critical Windows of Exposure
EDCs exposures health risks are closely associated to particular stages of life with concomitant
critical windows of exposure [13]. Considering EDCs mechanisms of action, embryonic development
and early life stages are certainly key critical windows of human exposure to these compounds.
Early development requires accurate timing of hormone action to endorse proper tissues and organs
growth and development. EDCs can affect the endogenous functioning of these hormones and with
enzymes implicated in xenobiotic biotransformation. Additionally, it is imperative to consider that, at
these stages, elimination processes are not fully developed [46,47]. Thus, during prenatal and early
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life stages of human development, exposing fetuses and young children to pollutants, such as EDCs,
through maternal blood and/or milk may enduringly reprogram physiologic processes prompting
health and/or reproductive dysfunctions later in life [48].
5.1. Embryonic Development
Exposure effects to environmental chemicals, which can comprise some EDCs, include direct
alterations on physiological mechanisms associated with gonadal development and function [49].
Pregnant women are exposed to mixtures of EDCs during pregnancy. Separating potential effects of
EDC exposure per se is extremely challenging, particularly when exposures are associated to common
sources. For example, serum levels of individual polychlorinated biphenyl (PCB) congeners are linked
with one another as well as with some organochlorine (OC) pesticides [50]. Additionally, numerous
studies have proven the transplacental transfer of xenoestrogens including POPs, flame retardants and
arsenic [51–53]. In addition, considerably high concentrations of BPA have been measured in human
placental samples as well as in fetal serum indicating that the placenta does not work as a barrier to BPA
and therefore developing human fetuses are chronically exposed to BPA with higher levels detected
in male fetuses [54]. Furthermore, glucuronidase-mediated BPA deconjugation in placenta and fetal
tissues has been advocated to contribute to substantial fetus exposure to free bioactive BPA [55].
Although estimating human exposure to BPA is still a controversial issue and several inconsistencies
have been described between the estimate intake levels and biomonitoring studies performed in
human blood/serum samples [22], BPA pharmacokinetic models based on hasty BPA glucuronidation
and urinary clearance [56,57] do not take into consideration possible BPA deconjugation processes
in specific tissues such as placenta. During early embryonic development, probable EDCs targets
comprise cell cleavage and differentiation, cell lineage determination, methylation, implantation,
maintenance of pregnancy and organogenesis [49]. A recently published study demonstrated that
in utero exposure to xenoestrogens may modify the placenta epigenome and that male descendants
appear to be particularly vulnerable to xenoestrogens exposure during prenatal development,
associated with alterations in DNA methylation of specific genomic repetitive sequences [58].
Additionally, some suggestive genes formerly correlated to birth weight, Type 2 diabetes, obesity or
steroid hormone signaling were found to be differentially methylated in males as a result of prenatal
xenoestrogen exposure [59]. Despise the scarce information regarding BPA effects on occupationally
exposed individuals, exposed to higher BPA levels, epidemiological studies demonstrated that parental
occupational exposure to this compound during pregnancy is correlated with decreased birth weight
of offspring [60] and with shortened anogenital distance in male offspring [61]. Moreover, a recently
published study demonstrated that perinatal exposure to EDCs mixtures relevant in the context
of human exposure resulted in altered female rat reproductive parameters such as reduced follicle
in pre-pubertal animals and relevantly in adult animals evidences for early female reproductive
senescence have also been described [62]. In addition, in zebrafish model, EDCs exposure of
individual compounds as well as their mixtures results in sexual differentiation effects associated to
histopathological alterations in the gonads of both males and females, with a sex ratio tendency towards
females and to permanent disruption of sexual development [63]. Understanding developmental
exposure effects of mixtures of EDCs and its underling mechanisms is critical to public health protection,
particularly in the context of both male and female reproductive disorders.
5.2. Early Life
The Developmental Origins of Health and Disease (DOHaD) hypothesis advocates that early
life experiences can have a significant impact in health outcomes later in life [64]. Newborns are
exposed to EDCs beginning during embryonic development, as discussed above, and therefore an
early body burden is probably derivative from in utero exposure. Cumulated evidence has emphasized
the critical role of early life environment in determining health outcomes of individuals and increasing
recent studies have demonstrated that early life perturbations affect the health of the succeeding
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generations [65]. For small infants, breast milk and artificial milk are the main sources of exposure.
Mixtures of lipophilic compounds (PCBs, brominated flame retardants, and dioxins) can be transferred
from the parental body burden to the newborn through breastfeeding, as breast-fed infants are a
population group with higher PBDE intake [66]. In the case of BPA, the most recent worldwide
biomonitoring study based on data from urinary BPA concentrations estimated human exposure to be
0.27 µg/kg body weight/day for the general population, 0.78 µg/kg body weight/day for children
and 0.45–1.61 µg/kg body weight/day for infants [67]. In addition to the contamination of breast milk
through the maternal exposure, the contamination of items utilized for nursing can also determine the
safety of newborns and infants diet. Although the various scientific assessments conducted by the
EFSA have recurrently concluded that there is no concern for human health [68], in 2011 the European
Legislation banned the use of BPA in the manufacture of baby bottles [69]. Another point of debate is
the immaturity of both hepatic detoxification and blood–brain barrier, which results in limited internal
defenses of neonates and infants against contaminants [70]. Considering the current pharmacokinetic
models, these factors increase the bioavailability of compounds such as BPA that undertake extensive
gut and liver glucuronidation, which leads to decreased levels of unmetabolized bioactive BPA that
enters the blood stream [56].
6. Male Vulnerability to EDCs
Several studies that focus on EDCs effects during embryonic development and early life, as
discussed above, indicate that, although both genders are affected by exposure to EDCs mixtures,
males appear to be particularly vulnerable to exposure of certain compounds. The epidemic
increase of male reproductive problems, which cannot be explained by genetic changes, has occurred
contemporaneously with cumulative exposures to various environmental factors through modern
lifestyle. Increasing evidence demonstrates that such exposures include EDCs mixtures which may be
associated with male reproductive disorders and diseases [71]. There has been substantial controversy
regarding the capacity of EDCs at lower than threshold concentrations levels to act together, particularly
when they have different mechanisms of action. Recent studies have demonstrated that low dose
mixtures of chemical reducing androgens, through different mechanisms, resulted in additive male
reproductive dysfunction [72,73]. Moreover, the antiandrogenic action of six binaries and one ternary
mixture of phthalates displaying complete antiandrogenic dose–response curves, and additionally
binary mixtures of phthalates and BPA at equi-effective doses evaluated in MDA-kb2 cells, displayed
a concentration addition model with a propensity to synergism at higher and antagonism at lower
doses [74]. Binary mixtures of five typical estrogens (estrone (E1), 17β-estradiol (E2), 4-n-octylphenol
(4-n-OP), 4-n-nonylphenol (4-n-NP) and BPA) resulted in an additive effect on serum vitellogenin
increase in male goldfish at low doses, and divergences associated with high dose exposures with
predicted additive effects exceeding those observed. Severe gonads atrophy was also described in all
the mixture treatment groups [75]. Exposure to mixtures of atrazine (ATR), perfluorooctanoic acid
(PFOA), BPA and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in pregnant mice resulted in significant
effects such as reversed lower neophobia levels in male offspring, showing a potential of these mixtures
for enhanced behavioral effects in males [76]. In occupational exposure context, increased mean
serum of BPA concentration has been associated with diminished mean androstenedione (AD) level
(0.18 ng/mL, 95% CI−0.22 to−0.13) and increased mean serum sex hormone-binding globulin (SHBG)
level (2.79 nmol/L, 95% CI 2.11–3.46) in male workers [77]. Additionally, BPA has also been positively
correlated with decreased semen quality and male infertility, for which induction of germ cell apoptosis
is considered a primary contributing factor [78], reduced sperm concentration, total sperm count,
vitality and motility [79], and alterations in laboratory parameters that may contribute to male infertility
such as, prolactin, estradiol and sex hormone-binding globulin (SHBG) [80]. Thus, the existing studies
indicate that BPA-exposed male workers had consistently higher risk of sexual dysfunction among all
domains of male sexual function than unexposed workers [81]. Additionally, PCB exposure has also
been associated with increased anogenital distance and prostate size and with diminished epididymal
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weight, epididymal sperm count, and motile epididymal sperm count (reviewed in [82]). Furthermore,
in vitro experiments have also demonstrated that low concentrations of the phytoestrogen genistein,
nonylphenol and 8-pre-nylnaringenin are more effective when combined in relation to the effects of
the compounds per se, on key processes of capacitation and acrosome reaction in human and mouse
spermatozoa [12]. Alterations in male reproductive functions, in rat, were reported to be more marked
in co-exposure experiments to genistein at low-dose (1 mg/kg/day) and the fungicide vinclozolin
(1 mg/kg/day) from conception to adulthood. On the other hand, similar to BPA, maternal genistein
supplement can decrease body weight in male offspring [83] and decreased percentage of normal
sperm and augmented abnormalities in semen morphology [84]. Additionally, genistein levels were
reported to be 2.67 times higher in patients with precocious puberty than those of the control which
indicate a potential role on this condition [85]. Concurrent with accumulating evidence from studies
suggesting that EDCs may contribute to male reproductive disorders and diseases, the burden of
male reproductive health problems is significant not only at individual and population levels but also
in economical contexts. Prevention of EDCs exposures has the potential to reduce the incidence of
several male reproductive disorders and diseases, and their associated health care and other social
costs, which, in the European Union, totals approximately €15 billion annually [71].
7. In Vitro Mixtures Effects
In vitro cell systems have been widely utilized for the assessment of low-dose effects of
well-known EDCs per se, and most studies have been directed to human cancer cell lines, particularly
breast cancer with associated effects on proliferation and gene expression (reviewed in [86]).
After article selection process, 14 articles were considered important for this review of EDCs mixtures
effects in human cell lines. Table 1 summarizes the reported effects of several EDCs mixtures in
the studied concentrations and utilized cell lines. In accordance with preceding data, our work
also demonstrated that breast cancer cells, particularly MCF7, are the most utilized cell lines for the
assessment of EDCs mixtures effects, although other cell lines have also been evaluated. Interestingly, in
MCF7, divergent results were reported when cells were exposed to different EDCs mixtures including
additive, greater-than-additive, antagonistic and synergistic interactions. Considering that activation
of divergent signaling pathways has been described for exposure to different concentrations of single
EDCs [87], we can postulate that, according to the reported findings, the same cell and tissues can
respond differently to EDCs mixtures, potentially by activation of different signaling pathways.
The term “low-dose” effects defines biological changes occurring in the concentration range of
typical human exposures or lower than the expected NOAEL level used to establish the oral reference
dosage (RfD) [88]. For the past years, “low-dose” effects have been a focal point of numerous studies
(reviewed in [89]). Here, we report that most of the performed studies have been conducted using
EDCs “low dose” mixture concentrations in the range of 10 pM to 10 µM, whereas a single study
evaluated both low and high doses effects of NP (0–100 µM) and BPA (0–5000 µM) [83]. Interestingly,
the most evaluated EDC in mixtures was BPA in the range of “low doses” [90].
Regarding EDCs mixture effects, the most frequently observed were undoubtedly additive effects,
particularly associated with cellular proliferation [38,90–95]. Nevertheless, greater-than-additive
interaction effects were also observed [89,93,95] as well as antagonistic and synergistic effects in cell
proliferation [90,92,94,96]. EDCs mixtures demonstrated endocrine disrupting potential via both
Estrogen (ER) and Androgen (AR) pathways [34]. Among the ER-dependent effects, we identified
additive interactions on estrogen receptor activation and estrogen-regulated pS2 gene transcription in
MCF7 cells [97], in Ovarian cancer cell line BG-1 suppression of BPA Estrogen receptor alpha (ERα)
mediated cell proliferation induced by genistein [39] and ER α and ER β activation additive effects in
MCF7 and HeLa cells [38]. Other EDCs mixture effects such as enhanced Ca2+ response [98], reduction
of phagocytosis disturbance of TNF-α, IL-1 β and IL-8 cytokine secretions [99] and synergistic effects
in ROS induction [44] were also identified.
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Table 1. Effect of EDCs mixtures in human cell lines.
EDCs Mixtures Concentrations Cell Lines Results References
o,p′-DDT, p,p′-DDT, p,p′-DDE, and β-hexachlorocyclohexane 1–10 nM MCF7 breast cancer cells Concentration additive effects [91]
E2, estrone, BPA, butyl benzylphthalate, endosulfan, methoxychlor,
and pentachlorophenol 10–400 nM MCF7 breast cancer cells
Additive, Antagonistic and
synergistic effects [90]
Benzo[a]pyrene, 1,2-benzanthracene, chrysene, methoxychlor, o,p′-DDT, dieldrin,
E2, and genistein
low range (individual chemical
thresholds) and a high range
(2–10 higher)
MCF7 breast cancer cells Concentration additivity;antagonistic effects [92]
17beta-estradiol (E2), ethinyl estradiol, diethylstilbestrol, epidermal growth factor,
insulin-like growth factor-I
E2/DES (0–10−9 M); EE
(0–10−10 M); E2 (0–10−10 M);
EGF/IGF-I (0–10−9 M)
MCF7 breast cancer cells Additive andgreater-than-additive interaction [93]
E2, EE2, genistein, BPA, 4-nonylphenol, and 4-tert-octylphenol - MCF7 breast cancer cells Additive and Antagonistic effects [94]
2-hydroxy-4-methoxy-benzophenone (BP-3), 2,4-dihydroxy benzophenone (BP-1),
octyl methoxy cinnamate (OMC) and 3-(4-methylbenzylidene) camphor (4-MBC) 100 nM–1 µM MCF7 breast cancer cells
Additive interaction;
Estrogen-regulated transcription [97]
BPA, Butylparaben, Coumestrol, o,p′-DDT, DES, Dienestrol, Endosulfan α (I),
Endosulfan β (II), 17β-estradiol, Estriol, Estrone, 17α-Ethinylestradiol, genistein,
β-HCH, Hexestrol, Kepone, Mestranol, Methoxychlor, Propyl paraben, Zearalenone
10 pM–10 nM MCF-7 breast cancer cells Normal and overestimatedconcentration additivity [95]
E2, BPA, genistein
GN 1.0, 2.5, 5.0, 7.5 and
10 × 10−5 M in the presence of
10−9 M of E2 or 10−5 M of BPA.
Ovarian cancer cell line BG-1 Suppression of BPA ERαmediated proliferation by GN [39]
Bitertanol, propiconazole, cypermethrin, terbuthylazine, malathion 10−10–10−5 M Human breast carcinomaMVLN cells ER, AR endocrine-disruption [34]
Homosalate, nonylparaben, padimate O, benzophenone-3, chlorophenothane,
triclosan, 3-(4-methylbenzylidene) camphor, benzal camphor, α-zearalenol,
4-octylphenol, dibutyl phthalate.
0.1, 1, and 10 µM Sperm cells Pronounced Ca2+ response. [98]
BPA, genistein and daidzein. 1 µM MCF7 and HeLa Additive effects [38]
Nonylphenol (NP) and BPA NP (0–100 µM)BPA (0–5000 µM)
Human Prostate Epithelial Cell
Line RWPE-1 Synergistic effects [96]
BPA, di-ethylhexyl-phthalate (DEHP), dibutyl phthalate (DBP) and
4-tert-octylphenol (4-OP) 0.001–10 µM
Human Macrophage-Like
THP-1 Cell
Reduction of phagocytosis;
disturbance ER-dependent effects [99]
Perfluorinated and brominated 10.000, 5000, 1000 and 500 timesthe serum levels
Human hepatocarcinoma
(HepG2) cells Synergistic effects [44]
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The results collected here clearly demonstrate that dose additivity, which has been utilized to
characterize mixtures effects of similar acting compounds such as EDCs [28] is not the only mechanism
of mixture toxicity and that in the same in vitro cell system (MCF7) exposure to different EDCs mixtures
results in divergent effects (e.g., Additive, Antagonistic and Synergistic).
8. Discussion
EDCs account for a substantial amount of chemicals that humans are constantly and continuously
environmentally exposed. Many of these chemicals are a result of industrialization and technological
development in the past century [7]. The current media scrutiny regarding the presence of harmful
chemicals in food and consumer goods has led to general public awareness of the effective simultaneous
exposure to multiple chemicals during daily life. Although the urge to assess combined exposure effects
is growing among experts, risk assessment of combined exposures such as EDCs mixtures still faces
major challenges [4], and potential hazardous effects of EDCs are still speculated based in findings from
classical epidemiological data of individuals and population studies [100]. There is irrefutable evidence
across multiple chemicals and organ systems concerning EDCs adverse effects in humans and human
cells, however the doses at which these effects may occur (occupational vs. environmental exposures)
remain unresolved for several compounds [31] and chemicals risk assessment, particularly in the
context of health risk assessment, typically does not take in account effects of combined exposures.
Additionally, EDCs, similar to hormones, do follow non-monotonic dose responses (NMDR) curves
such as inverted U-shaped curves, which means that low dose exposures effects cannot be predicted
by observed effects of higher doses, which increases the difficulty for risk assessment and the potential
of mixtures unpredictable interactions [100].
Furthermore, the complexity of EDCs mixtures concerning compounds with short or long
half-lives is also of key importance to conduct valuable risk assessments. It is acknowledged that
compounds with long half-lives have higher reliability in exposure assessments, whereas short-half-life
EDCs are rapidly metabolized and eliminated [100]. However, these claims do not take into account
compounds that can be bioaccumulated in particular tissues of the human organism. In the case of
BPA, considered a short-half-life EDCs [56,57], several inconsistencies have been described between
estimated intake levels obtained from urinary human samples and biomonitoring studies performed
in human blood/serum regarding the steady-state presence of unmetabolized BPA [22], which can be
10-fold higher than the worst case predictions for daily exposure [101]. In addition, substantially high
concentrations of BPA measured in human placental samples when compared to urine or blood/serum
indicates a potential for bioaccumulation. It is currently acknowledged that health hazardous outcomes
associated with EDCs exposures may be closely associated with particular vulnerable life stages with
concomitant critical windows of exposure [13]. Embryonic development and early life stages are most
certainly critical windows of exposure to EDCs, as early development requires accurate timing of
hormone action to promote proper tissues and organs growth and development.
During pregnancy, mother and embryo/fetus establish an extremely intimate contact in which
several molecules are involved. In the feto–maternal interface, hormones such as estrogens and
progesterone are major players for the necessary and accurate endocrine regulation in which the
placenta has a central role. Human placenta is crucial to sustain pregnancy and assure fetal
development and growth, and it is assumed to be a protective organ capable of blocking the passage
of harmful compounds to the fetus. However, the placenta is not adapted to prevent the passage of
man-made compounds that humans have been environmentally and/or occupationally exposed for
the past several decades; therefore, fetal exposure to these potentially hazardous compounds cannot be
avoided. The placenta is highly sensitive estrogenic activity as it expresses both ERα and ERβ classical
estrogen receptors, and, due to its high lipophilicity, environmental EDCs can evade the placental
barrier [102]. EDCs have been reported to be transplacental transferred, which indicates that, during
embryonic development, the fetus is chronically exposed to mixtures of these compounds, potentially
resulting in an early “body burden”, with potentially associated hazardous effects later in live. On the
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other hand, as discussed above, prenatal exposure to mixtures of xenoestrogens can change epigenetic
marks (DNA methylation) patterns in placenta tissues and particular genetic and epidemiological studies
demonstrated that parental exposure to EDCs during pregnancy is correlated with decreased birth weight
of offspring and shortened anogenital distance in male offspring. Considering the data presented in this
work, it is perfectly reasonable to hypothesize that early life EDCs effects may permanently reprogram
physiologic processes influencing future health and/or reproductive function [48].
Furthermore, endocrine disruption, mainly associated with estrogenic compounds is also of
particular concern for puberty development in males because, during this life stage, accurate endocrine
regulation is crucial for the normal development of male secondary sexual characteristics. Currently,
it is acknowledged that EDCs can alter the pubertal process by either enhance the advent of puberty
(genistein and BPA) or by delay the pubertal onset (Dioxin) [103]. The significance of these findings
must be highlighted, as it suggests that EDCs mixtures exposure at sensitive periods of development
are likely to cause pronounced detrimental effects on male reproductive system including infertility
which is presently a major medical concern.
The results discussed here emphasize the need for further studies to assess additive or
synergistic effects of EDC mixtures, particularly during critical and vulnerable life stages and on
male reproductive system. Further research must be performed to accurately understand EDCs,
principally regarding endocrine systems and mechanistic considerations: (i) normal homeostatic
mechanisms (e.g., down-regulation of receptor expression), which may compensate possible effects
in adulthood exposures; (ii) exposure during the period of programming of the endocrine system
in progress (critical window of exposure) may result in permanent change of function or sensitivity
to stimulatory/inhibitory signals; (iii) exposure to the same concentrations of an endocrine signal at
different stages in life history may produce different effects; (iv) because of cross talk between different
endocrine systems, effects may occur unpredictably; and (v) considerable caution should be exerted in
extrapolating in vitro measures of hormonal activity to the situation in vivo [89].
In the context of risk assessment, further considerations should be taken into account, namely
the enforcement of biomonitoring of effective doses that could allow the detection of scenarios in
which mixture effects may be present, even when the effect would not be predicted from single
chemical information, for example with effect-directed fractionation to identify components that
should be targets for regulatory attention [3]. However, one of the most important methodological
limitations that EDCs mixtures studies face is the fact that, due to the ubiquitous presence of EDCs in
the environment and food chain, humans are consistently and chronically exposed to these compounds,
which results in an inexistence of negative control groups, i.e., individuals with no contact or exposure
to EDCs. These continuous long term exposures in addition to the complexity of short- or long-half-life
compounds and bioaccumulation processes still lead to the great challenge of reliably measuring EDCs
internal concentrations. The integration of the omics approach combined with state-of-the-art in vitro
cell culture models has the potential to considerably improve our understanding of chemical and drug
induced perturbations and the replication of reported evidence in independent datasets could provide
valid association findings. Nevertheless, considering there are numerous compounds with suspected
endocrine disruption potential, to achieve an efficient design, repeated measurements throughout life
would have to be performed.
Moreover, it is also important to note that several studies have demonstrated that EDCs effects,
particularly at low doses, have associated cell type specificities [104,105]. Thus, cellular effects may vary
depending of the utilized in vitro cell systems. The combination of mechanistic toxicity and biokinetics
will allow an unparalleled understanding of dynamics and kinetics which can help build prediction
models for risk assessment [106] and help to further disclose the unsolved dilemma of synergistic,
additive, or antagonistic effects of EDC mixtures. In the next years, educating the public, media,
politicians, and governmental agencies on the possible elimination of EDCs from food, water, and air
and the creation of products that can test and eliminate potential EDCs are of foremost importance.
Additionally, future international collaboration that can assure EDC research funding in basic, clinical,
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and epidemiological realms is also imperative, especially considering that the cost of research and
prevention will result in substantial cost savings in both treatment and mitigation [31].
9. Conclusions
Considering the global massive production and consumption of items containing EDCs and
consequently the increasing number of individuals exposed to mixtures of these compounds, including
pregnant women and young children, where the most damaging impact on later life disease
development or abnormal physiology occurs, this overview evidences the urgency of developing and
performing valuable and accurate risk assessments to protect exposed individuals and their descendants
from the potential hazardous effects of aggregate EDCs mixtures. Importantly, the complexity of EDCs
exposure assessments, particular concerning mixture risk assessments, must be carefully considered,
and the design of doctrines and data interpretation may require new methodological concepts.
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